<DOC>
	<DOCNO>NCT00146770</DOCNO>
	<brief_summary>This study conduct collect additional long-term efficacy safety data Aldurazyme® ( laronidase ) patient MPS I disease . Patients previously enrol Phase 3 Double-Blind Study enrol study .</brief_summary>
	<brief_title>Phase 3 Extension Study Safety Efficacy Aldurazyme® ( Laronidase ) Mucopolysaccharidosis I ( MPS I ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>The patient patient 's legal guardian must provide write informed consent prior protocolrelated procedure perform . The patient must successfully complete Study ALID00399 ( receive 21 26 consecutive weekly infusion ) . The patient experience safety issue would contraindicate participation Extension study . A female patient childbearing potential must negative pregnancy test entry The patient pregnant lactating . The patient receive investigational drug within 30 day prior study enrollment . The patient medical condition , serious intercurrent illness , extenuate circumstance may significantly interfere study compliance include prescribed evaluation followup activity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>